Michael Pavlides
Head of liver imaging at OCMR
- Principal Investigator
- Honorary consultant at Oxford University Hospitals NHS Trust
Recent publications
Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D.
Journal article
Pennisi G. et al, (2026), Hepatology, 84
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.
Journal article
Pavlides M. et al, (2026), Nat Med
Editorial: Prediction of Survival in Hepatocellular Cancer—Rise and Fall of the Machines
Journal article
Pavlides M., (2026), Alimentary Pharmacology & Therapeutics
Lowering the bar? Noninvasive tests for identifying significant fibrosis in metabolic dysfunction-associated steatotic liver disease.
Journal article
Pavlides M. and Appiah E., (2026), Pol Arch Intern Med, 136
Changes in hepatic L-carnitine levels in people with metabolic dysfunction-associated steatotic liver disease (MASLD) assessed by magnetic resonance techniques.
Journal article
Savic D. et al, (2026), Sci Rep